APM Earnings — Aptorum Group Limited Class A Ordinary Shares Post-ER Performance | BigEarnings
APM — Aptorum Group Limited Class A Ordinary Shares
XNAS
Price$0.85
Market Cap$6.9M
P/E—
52W Range$0.65 – $4.47
Next Earnings2026-10-02
About Aptorum Group Limited Class A Ordinary Shares
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
